Prosecution Insights
Prosecution Insights
7 pending office actions • 6 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (57%) |
| §102 only | 1 (14%) |
| §112 only | 1 (14%) |
| No statute on record | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DENT, ALANA HARRIS | 2 | 44.6% | +32.4% |
| MCKOY, QUINCY ANDRE | 1 | 68.5% | +41.7% |
| FISHER, MELISSA L | 1 | 44.2% | +42.3% |
| CHO, DAVID H | 1 | 38.2% | +75.0% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.4% |
| PECKHAM, RICHARD GRANT | 1 | 68.3% | +35.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18473540 | Methods Of Treating Cancer With Transmembrane Protein 16F (TMEM16F) Inhibitors | MCKOY, QUINCY ANDRE | 73d overdue |
| 17758495 | Estrogen Metabolite Levels And Cancer Driver Gene Mutations In Lung Cancer Risk Stratification And Treatment | CHO, DAVID H | 31d overdue |
| 16310566 | Active Alpha-5-Beta-1 Integrin As A Biomarker For Enhancing Tumor Treatment Efficacy | DENT, ALANA HARRIS | 9d overdue |
| 17613267 | PI3K/LYN-ACLY Signaling Inhibition | HUANG, GIGI GEORGIANA | 5d overdue |
| 18273868 | Treatment Of Integrin-Related Disorders With Stapled Peptides | FISHER, MELISSA L | 4d overdue |
| 17527536 | THEOPHYLLINE DERIVATIVES FOR REPRESSING CANCER CELL GROWTH | PECKHAM, RICHARD GRANT | 2d overdue |
| 17055722 | Urinary DNA Detection For Urothelial Cancer | DENT, ALANA HARRIS | 20d |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1626 | 1 |
| 1658 | 1 |
| 1693 | 1 |
| 1613 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18473540 | Methods Of Treating Cancer With Transmembrane Protein 16F (TMEM16F) Inhibitors | MCKOY, QUINCY ANDRE | 1626 | §102 | Non-Final OA | 73d overdue | Pending | Sep 25, 2023 |
| 18273868 | Treatment Of Integrin-Related Disorders With Stapled Peptides | FISHER, MELISSA L | 1658 | §112 | Non-Final OA | 4d overdue | Pending | Jul 24, 2023 |
| 17758495 | Estrogen Metabolite Levels And Cancer Driver Gene Mutations In Lung Cancer Risk Stratification And Treatment | CHO, DAVID H | 1693 | Other | Non-Final OA | 31d overdue | Pending | Jul 07, 2022 |
| 17613267 | PI3K/LYN-ACLY Signaling Inhibition | HUANG, GIGI GEORGIANA | 1613 | §103 | Final Rejection | 5d overdue | Pending | Nov 22, 2021 |
| 17527536 | THEOPHYLLINE DERIVATIVES FOR REPRESSING CANCER CELL GROWTH | PECKHAM, RICHARD GRANT | 1627 | §103 | Non-Final OA | 2d overdue | Pending | Nov 16, 2021 |
| 17055722 | Urinary DNA Detection For Urothelial Cancer | DENT, ALANA HARRIS | 1643 | §103 | Final Rejection | 20d | Pending | Nov 16, 2020 |
| 16310566 | Active Alpha-5-Beta-1 Integrin As A Biomarker For Enhancing Tumor Treatment Efficacy | DENT, ALANA HARRIS | 1643 | §103 | Final Rejection | 9d overdue | Pending | Dec 17, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial